Real‐world clinical outcomes of olaparib therapy in Chinese patients with advanced serous ovarian cancer treated in Macau

BACKGROUND: Olaparib has been approved as an active and maintenance therapy for patients with platinum‐sensitive, BRCA‐mutated high‐grade serous ovarian cancer (SOC). However, the efficacy and safety data is lack among Chinese ovarian cancer patients. AIM: This real‐world study aimed to evaluate the effectiveness and safety profile of olaparib in patients from mainland China, where olaparib is currently unavailable. METHODS AND RESULTS: This single‐center, observational study included 65 patients with pathologically confirmed advanced serous ovarian cancer from Kiang Wu Hospital in Macau between December 2015 and September 2017. Progression‐free survival (PFS) and other endpoints (treatment response, disease progression, and adverse events) were evaluated. PFS was estimated using the Kaplan‐Meier method. The median treatment duration was 4 months (range, 1‐15). The median PFS for the overall population was 4.2 months (95% CI 2.7‐5.2), while those for patients with wild‐type BRCA1/2 and BRCA1/2 mutations were 3.1 months (95% CI 1.3‐4.6) and 5.3 months (95% CI 2.8‐7.1), respectively. The median PFS tended to be longer for patients on maintenance therapy (between 9.0 months [95% CI 1.4‐17.5] and 10.0 months [95% CI 2.5‐18.1]) than for those on active therapy (between 3.1 months [95% CI 2.1‐3.8] and 3.0 months [95% CI 1.4‐4.5]). Most patients (87.0%) experienced low‐grade adverse events; the most common of which were fatigue (49.0%) and nausea (35.0%). CONCLUSION: Our findings demonstrate clinical benefit of olaparib to mainland Chinese patients with high‐grade SOC, particularly for patients with BRCA mutations and who require maintenance therapy.